Once-weekly erythropoietic therapy: Is there a difference between the available preparations?

Nephrology Dialysis Transplantation

Volumn 17, Issue 12, 2002, Pages 2047-2051

  Macdougall, Iain C ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

Darbepoetin alfa; Epoetin; Epoetin beta; Erythropoietic therapy

Indexed keywords

HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; DRUG DERIVATIVE; ERYTHROPOIETIN;

ANEMIA; ARTICLE; CHRONIC KIDNEY FAILURE; CLINICAL STUDY; CLINICAL TRIAL; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; HUMAN; KIDNEY FAILURE; PRIORITY JOURNAL; DRUG ADMINISTRATION; NOTE; RENAL REPLACEMENT THERAPY;

ANEMIA; DRUG ADMINISTRATION SCHEDULE; ERYTHROPOIETIN; HUMANS; KIDNEY FAILURE; PERITONEAL DIALYSIS, CONTINUOUS AMBULATORY; RENAL DIALYSIS;

EID: 0036899603     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/17.12.2047     Document Type: Article

References (30)

1. Saleh A, Krane NK, Caballero M, Starks E. Once weekly subcutaneous erythropoietin is an effective therapy in the treatment of anemia of end stage renal disease patients on CAPD. Adv Perit Dial 1991; 7: 288-291
2. Hisano S, Kaku Y, Ueda K, Onoyama K. Efficacy of once weekly erythropoietin therapy in children on continuous ambulatory peritoneal dialysis. Acta Paediatr Jpn 1991; 33: 450-454
3. Lui SF, Law CB, Ting SM, Li P, Lai KN. Once weekly versus twice weekly subcutaneous administration of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis. Clin Nephrol 1991; 36: 246-251
4. Goldraich I, Goldraich N. Once weekly subcutaneous administration of recombinant erythropoietin in children treated with CAPD. Adv Perit Dial 1992; 8: 440-443
5. Lui SF, Wong KC, Li PK, Lai KN. Once weekly versus twice weekly subcutaneous administration of recombinant human erythropoietin in haemodialysis patients. Am J Nephrol 1992; 12: 55-60
6. Austrian Multicenter Study Group in Predialysis Patients. Effectiveness and safety of recombinant human erythropoietin in predialysis patients. Nephron 1992; 61: 399-403
7. Ongkingco JR, Ruley EJ, Turner ME, Fragale MR. Efficacy of once- versus thrice-weekly subcutaneous recombinant human erythropoietin in children receiving continuous cycling peritoneal dialysis. Am J Nephrol 1994; 14: 14-18
8. Hussain R, Naqvi SA. Once weekly subcutaneous administration of erythropoietin in haemodialysis patients. J Pak Med Assoc 1994; 44: 88-90
9. Lago M, Perez-Garcia R, Garcia de Vinuesa MS, Anaya F, Valderrabano F. Efficiency of once-weekly subcutaneous administration of recombinant human erythropoietin versus three times a week administration in hemodialysis patients. Nephron 1996; 72: 723-724
10. Frifelt JJ, Tvedegaard E, Bruun K et al. Efficacy of recombinant human erythropoietin administered subcutaneously to CAPD patients once weekly. Perit Dial Int 1996; 16: 594-598
11. Yagil Y. Proposed therapeutic algorithm for the treatment of anemia of chronic renal failure in pre-dialysis patients with low dose weekly subcutaneous r-HuEPO. Multicenter Study Group. Isr J Med Sci 1997; 33: 36-44
12. Macdougall IC. Novel erythropoiesis stimulating protein. Semin Nephrol 2000; 20: 375-381
13. Egrie JC, Browne JK. Development and characterization of novel erythropoiesis stimulating protein (NESP). Nephrol Dial Transplant 2001; 16 [Suppl 3]: 3-13
14. Macdougall IC, Gray SJ, Elston O et al. Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. J Am Soc Nephrol 1999; 10: 2392-2395
15. Macdougall IC on behalf of the UK NESP Study Group. Novel erythropoiesis stimulating protein (NESP) for the treatment of renal anaemia. J Am Soc Nephrol 1998; 9: 258A-259A
16. Locatelli F, Olivares J, Walker R et al. Novel erythropoiesis stimulating protein for treatment of anemia in chronic renal insufficiency. Kidney Int 2001; 60: 741-747
17. Coyne D, Ling BN, Toto R et al. Novel erythropoiesis stimulating protein (NESP) corrects anemia in dialysis patients when administered at reduced dose frequency compared with recombinant human erythropoietin (r-HuEPO). J Am Soc Nephrol 2000; 11: 1380
18. Vanrenterghem Y, Barany P, Mann J et al. on behalf of the European/Australian NESP 970200 Study Group. Novel erythropoiesis stimulating protein (NESP) maintains hemoglobin in ESRD patients when administered once weekly or once every other week. J Am Soc Nephrol 1999; 10: 270A
19. Nissenson AR, Swan SK, Lindberg JS et al. Novel erythropoiesis stimulating protein (NESP) safely maintains hemoglobin concentration levels in hemodialysis patients as effectively as r-HuEPO when administered once weekly. J Am Soc Nephrol 2000; 11: 252A
20. Graf H, Lacombe JL, Braun J, Gomes da Costa AA. Novel erythropoiesis stimulating protein effectively maintains hemoglobin when administered at a reduced dose frequency compared with recombinant human erythropoietin (r-HuEPO) in dialysis patients. J Am Soc Nephrol 2000; 11: 250A
21. Braun J on behalf of the 20000144 Study Group. Darbepoetin alfa administered once every 4 weeks maintains Hb levels in patients with chronic kidney disease receiving dialysis. Nephrol Dial Transplant 2002; 17 (Abstracts Suppl 1): 136
22. Weiss LG, Clyne N, Divino Fihlho J, Frisenette-Fich C, Kurkus J, Svensson B on behalf of the Swedish Study Group. The efficacy of once weekly compared with two or three times weekly subcutaneous epoetin beta: results from a randomized controlled multicentre trial. Nephrol Dial Transplant 2000; 15: 2014-2019
23. Locatelli F, Baldamus CA, Villa G, Ganea A, Martin de Francisco AL. Once-weekly compared with three-times-weekly subcutaneous epoetin beta: results from a randomized, multi-center, therapeutic-equivalence study. Am J Kidney Dis 2002; 40: 119-125
24. Grzeszczak W, Sulowicz W, Rutowski B et al. on behalf of the European Collaborative Group. Once weekly and once fort-nightly (every 2 weeks) subcutaneous epoetin beta is effective in PD patients with chronic renal anaemia. Nephrol Dial Transplant 2002; 17 (Abstracts Suppl 1): 24
25. Jones CH, Ridley L, Richardson D. Which EPO dose per week? Nephrol Dial Transplant 2002; 17: 1855
26. Geddes C, Worjtzcak V, Adams A, McPherson M, French C. Does erythropoietin requirement increase with reduced frequency of administration? Abstract from Scottish Renal Association Meeting, Cumbernauld, April 2002.
27. Provenzano R, Morrison L. Once-weekly treatment with epoetin alfa in patients with anemia due to chronic kidney disease: preliminary analysis. J Am Soc Nephrol 2001; 12: 238A
28. Barre P, Reichel H, Suranyi MG. Once weekly epoetin alfa (Eprex/Erypo) maintains haemoglobin concentrations in haemodialysis patients. Nephrol Dial Transplant 2002; 17 (Abstracts Suppl 1): 136
29. Cheung W, Minton N, Gunawardena K. Pharmacokinetics and pharmacodynamics of epoetin alfa once weekly and three times weekly. Eur J Clin Pharmacol 2001; 57: 411-418
30. Horl W. IV darbepoetin alfa is more effective than i.v. rHuEPO in maintaining target Hb concentrations in patients with renal anaemia. Nephrol Dial Transplant 2002; 17 (Abstracts Suppl 1): 24